Therapeutic Monoclonal Antibodies: Past, Present, and Future

Therapeutic Monoclonal Antibodies: From Bench to Clinic

Volumn , Issue , 2009, Pages 1-50

  Strohl, William R ^a  

^a CENTOCOR INC   (United States)

Author keywords

Antibody basics, therapeutic monoclonal antibodies past, present and future; From biotechnology to biopharma; Technologies leading to current monoclonal antibody engineering environment

Indexed keywords

EID: 84890981704     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470485408.ch1     Document Type: Chapter

References (164)

1. Abhinanden, K.R., and A.C. Martin. 2007. Analyzing the "degree of humanness" of antibody sequences. J. Mol. Biol. 369:852-862.
2. Adams, G.P., R. Schier, A.M. McCall, H.H. Simmons, E.M. Horak, R.K. Alpaugh, J.D. Marks, and L.M. Weiner. 2001. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61:4750-4755.
3. Alkan, S.S. 2004. Monoclonal antibodies: The story of a discovery that revolutionized science and medicine. Nature Rev. Immunol. 4:153-156.
4. Alegre, M.L., L.J. Peterson, D. Xu, H.A. Sattar, D.R. Jeyarajah, K. Kowalkowski, J.R. Thistlewaite, R.A. Zivin, L. Jolliffe, and J.A. Bluestone. 1994. A non-activating "humanized" anti-CD3 monoclonal antibody retains innunosuppressive properties in vivo. Transplantation 57:1537-1543.
5. Alt, F.W., T.K. Blackwell, and G.D. Yancopoulos. 1985. Immunoglobulin genes in transgenic mice. Trends Genet. 1:231-236.
6. Anthony, R.M., F. Nimmerjahn, D.J. Ashline, V.N. Reinhold, J.C. Paulson, and J.V. Ravetch. 2008. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320:373-376.
7. Baeuerle, P.A., C. Reinhardt, and P. Kufer. 2008. BiTE: A new class of antibodies that recruit T-cells. Drugs Future 33:137-147.
8. Barbas, C.F. III, J.D. Bain, D.M. Hoekstra, and R.A. Lerner. 1992. Semisynthetic combinatorial antibody libraries: A chemical solution to the diversity problem. Proc. Natl. Acad. Sci. USA 89:4457-4461.
9. Barbas, C.F. III, A.S. Kang, R.A. Lerner, and S.J. Benkovic. 1991. Assembly of combinatorial antibody libraries on phage surfaces: The gene III site. Proc. Natl. Acad. Sci. USA 88:7978-7982.
10. Bass, S., R. Greene, and J.A. Wells. 1990. Hormone phage: An enrichment method for variant proteins with altered binding properties. Proteins 8:309-314.
11. Beers, S.A., C.H. Chan, S. James, R.R. French, K.E. Attfield, C.M. Brennan, A. Ahuja, M.J. Shlomchik, M.S. Cragg, and M.J. Glennie. 2008. Type II (tositumomab) anti-CD20 monoclonal antibody out performs Type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 112:41704177.
12. Behring, E.A., and S. Kitasato. 1890. Ueber das Zustandekommen der Diphtherie-Immunitaet und der Tetanus-Immunitaet bei Thieren. Deutsch. Med. Wochenschr. 49:1113-1114.
13. Beidler, C.B., J.R. Ludwig, J. Cardenal, J. Phelps, C.G. Papworth, E. Melcher, M. Sierzega, L.J. Myers, B.W. Unger, M. Fisher, et al. 1988. Cloning and high level expression of a chimeric antibody with specificity for human carcinoembryonic antigen. J. Immunol. 141:4053-4060.
14. Bello, C., and E.M. Sotomayor. 2007. Monoclonal antibodies for B-cell lymphomas: Rituximab and beyond. Hematology Am. Soc. Hematol. Educ. Program 2007:233-242.
15. Better, M., C.P. Chang, R.R. Robinson, and A.H. Horwitz. 1988. Escherichia coli secretion of an active chimeric antibody fragment. Science 240:1041-1043.
16. Bitonti, A.J., J.A. Dumont, S.C. Low, R.T. Peters, K.E. Kropp, V.J. Palombella, J.M. Stattel, Y. Lu, C.A. Tan, J.J. Song, A.M. Garcia, N.E. Simister, G.M. Spiekermann, W.I. Lencer, and R.S. Blumberg. 2004. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. USA 101:9763-9768.
17. Boulianne, G.L., N. Hozumi, and M.L. Shulman. 1984. Production of functional chimaeric mouse/human antibody. Nature 312:643-646.
18. Brennan, M., P.F. Davison, and H. Paulus. 1985. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229:81-83.
19. Brüggemann, M., G.T. Williams, C.I. Bindon, M.R. Clark, M.R. Walker, R. Jefferis, H. Waldmann, and M.S. Neuberger. 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 66:1351-1361.
20. Bruton, O.C. 1952. Agammaglobulinemia. Pediatrics 9:722-727.
21. Bugelski, P.J., R.J. Capocasale, D. Makropoulos, D. Marshall, P.W. Fisher, J. Lu, R. Achuthanandam, T. Spinka-Doms, D. Kwok, D. Graden, A. Voklk, T. Nesspor, I.E. James, and C. Haung. 2008. CNTO 530: Molecular pharmacology in human UT-7EPO cells and pharmacokinetics in mice. J. Biotechnol. 134:171-180.
22. Capon, D.J., S.M. Chamow, J. Mordenti, S.A. Marsters, T. Gregory, H. Mitsuya, R.A. Byrn, C. Lucas, F.M. Wurm, J.E. Groopman, et al. 1989. Designing CD4 immunoadhesins for AIDS therapy. Nature 337:525-531.
23. Carter, P.J. 2006. Potent antibody therapeutics by design. Nature Rev. Immunol. 6:343-357.
24. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bordos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in igG Fc receptor FcgammaRilla gene. Blood 99:754-758.
25. Casadevall, A. 1996. Antibody-based therapies for emerging infectious diseases. Emerg. Infect. Dis. 2:200-208.
26. Casadevall, A. 2002. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis. 8:833-841.
27. Casadevall, A., and M.D. Scharff. 1995. Return to the past: The case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. 21:150-161.
28. Chatenoud, L., C. Ferran, C. Legendre, I. Thouard, S. Merite, A. Reuter, Y. Gevaert, H. Kreis, P. Franchimont, and J.F. Bach. 1990. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49:697-702.
29. Chowdhury, P.S., and H. Wu. 2005. Tailor-made antibody therapeutics. Methods 36:11-24.
30. Chung, K.T. n.d. Emil Von Behring (1854-1917). Pioneerof serology. http://www.mhhe.com/biosci/cellmicro/nester/graphics/nester3ehp/common/vonbehr.html
31. Co, M.S., and C. Queen. 1991. Humanized antibodies for therapy. Nature 351:501-502.
32. Cohen, S.N., A.C. Chang, H.W. Boyer, and R.B. Helling. 1973. Construction of biologically functional bacterial plasmids in vitro. Proc. Natl. Acad. Sci. USA 70:3240-3244.
33. Colcher, D., G. Pavlinkova, G. Bresford, B.J. Booth, A. Choudhury, and S.K. Batra. 1998. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Quarterly J. Nucl. Med. 42:225-241.
34. Coloma, M.J., and S.L. Morrison. 1997. Design and production of novel tetravalent bispecific antibodies. Nature Biotechnol. 15:159-163.
35. Cragg, M.S., and M.J. Glennie. 2004. Antibody specificity controls in vivo effector mechanisms of anti CD20 reagents. Blood 103:2738-2743.
36. Dalbadie-McFarland, G., L.W. Cohen, A.D. Riggs, C. Morin, K. Itakura, and J.H. Richards. 1982. Oligonucleotide-directed mutagenesis as a general and powerful method for studies of protein function. Proc. Natl. Acad. Sci. USA 79:6409-6413.
37. Dall'Acqua, W.F., P.A. Kiener, and H. Wu. 2006. Properties of human IgG1 engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281:23514-23524.
38. De Kraif, J., L. Terstappen, E. Boel, and T. Logtenberg. 1995. Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage display library. Proc. Natl. Acad. Sci. USA 92:3938-3942.
39. De la Cruz Edmonds, M.C., M. Tellers, C. Chan, P. Salmon, D.K. Robinson, and J. Markussen. 2006. Development of transfection and high-producer screening protocols for the CHOK1SV cell system. Mol. Biotechnol. 34:179-190.
40. Dimitrov, D.S., and J.D. Marks. 2008. Therapeutic antibodies: Current state and future trends-is a paradigm change coming soon? Methods Mol. Biol. 525:1-27.
41. Doppalapudi, V.R., N. Tryder, L. Li, D. Griffith, F.F. Liao, G. Roxas, M.P. Ramprasad, C. Bradshaw, and C.F. Barbas, III. 2007. Chemically programmed antibodies: Endothelin receptor targeting CovX-bodies. Bioorg. Med. Chem. Lett. 17:501-506.
42. Dumoulin, M., K. Conrath, A. Van Meiraeghe, E. Meersman, K. Meersman, L.G. Frenken, S. Muyldermans, L. Wyns, and A. Matagne. 2002. Single-domain antibody fragments with high conformational stability. ProteinSci. 11:500-515.
43. H. Cell 19:981-992.
44. Fellouse, F.A., K. Esaki, S. Birtalan, D. Raptis, V.J. Cancasci, A. Koide, P. Jhurani, M. Vasser, C. Weismann, A.A. Kossiakoff, S. Koide, and S.S. Sidhu. 2007. High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. J. Mol. Biol. 373:924-940.
45. Feng, Y., and D.S. Dimitrov. 2008. Monoclonal antibodies against components of the IGF system for cancer treatment. Curr. Opin. Drug Disc. Develop. 11:178-185.
46. Ghielmini, M., K. Rufibach, G. Salles, L. Leoncini-Franscini, C. Leger-Falandry, S. Cogliatti, M. Fey, G. Martinelli, R. Stahel, A. Lohri, N. Ketterer, M. Wernli, T. Cerny, and S.F. Schmitz. 2005. Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for ClinicalCancerResearch (SAKK). Ann. Oncol. 16:1675-1682.
47. Glennie, M.J., R.R. French, M.S. Cragg, and R.P. Taylor. 2007. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44:3823-3837.
48. Goeddel, D.V., H.L. Heyneker, T. Hozume, R. Arentzen, K. Itakura, D.G. Yansura, M.J. Ross, G. Miozzari, R. Crea, and P.H. Seeburg. 1979a. Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature 281:544-548.
49. Goeddel, D.V., D.G. Kleid, F. Bolivar, G.L. Heyneker, D.G. Yansura, R. Crea,T. Hirose, A. Kraszewski, K. Itakura, and A.D. Riggs. 1979b. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc. Natl. Acad. Sci. USA 76:106-110.
50. Gough, N.M., and O. Bernard. 1981. Sequences of the joining region genes for immunoglobulin heavy chains and their sole in generation of antibody diversity. Proc. Natl. Acad. Sci. USA 78:509-513.
51. Gram, H., L.A. Marconi, C.F. Barbas III, T.A. Collet, R.A. Lerner, and A.S. Kang. 1992. In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc. Natl. Acad. Sci. USA 89:3576-3580.
52. Green, L.L. 1999. Antobody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods 231:11-23.
53. Green, L.L., M.C. Hardy, C.E. Maynard-Currie, H. Tsuda, D.M. Tsuda, D.M. Louie, M.J. Mendez, H. Abderrahim, M. Noguchi, D.H. Smith, Y. Zeng, et al. 1994. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nature Genet. 7:13-21.
54. Griffiths, A.D., S.C. Williams, O. Hartley, I.M. Tomlinson, P. Waterhouse, W.L. Crosby, R.E. Kontermann, P.T. Jones, N.M. Low, T.J. Allison, et al. 1994. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13:3245-3260.
55. Gronski, P., F.R. Seiler, and H.G. Schwick. 1991. Discovery of antitoxins and development of antibody preparations for clinical uses from 1890 to 1990. Mol. Immunol. 28:1321-1332.
56. Hagenbook, A., T. Plesner, P. Johnson, et al. 2005. HuMax-Cd20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma. Blood 106:4760a.
57. Haller, C.A., M.E. Cosenza, and J.T. Sullivan. 2008. Safety issues specific to clinical development of protein therapeutics. Clin. Pharm. Therap. 84:624-627.
58. Harmsen, M.M., and H. De Haard. 2007. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 77:13-22.
59. Hawkins, R.E., S.J. Russel, and G. Winter. 1992. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J. Mol. Biol. 226:889-896.
60. He, M., and F. Khan. 2005. Ribosome display: Next generation display technologies for production of antibodies in vitro. Expert Rev. Proteom. 2:421-430.
61. Hoet, R.M., E.H. Cohen, R.B. Kent, K. Rookey, S. Schoonbroodt, S. Hogan, L. Rem, N. Frans, M. Daukandt, H. Pieters, R. van Hegelsom, N.C. Neer, H.G. Nastri, I.J. Rondon, J.A. Leeds, S.E. Hufton, L. Huang, I. Kashin, M. Devlin, G. Kuang, M. Steukers, M. Viswanathan, A.E. Nixon, D.J. Sexton, G.R. Hoogenboom, and R.C. Charles Ladner. 2005. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nature Biotechnol. 23:344-348.
62. Honegger, A. 2008. Engineering antibodies for stability and efficient folding. Handbook Exp. Pharmacol. 181:47-68.
63. Hoogenboom, H.R. 2005. Selecting and screening recombinant antibody libraries. Nature Biotechnol. 23:1105-1116.
64. Hozumi, N., and S. Tonegawa. 1976. Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. Proc. Natl. Acad. Sci. USA 73:3628-3632.
65. Hutchinson, C.A., S. Philips, M.H. Edgell, S. Gillam, P. Jahnke, and M. Smith. 1978. Mutagenesis at a specific position in a DNA sequence. J. Biol. Chem. 253:6551-6560.
66. Hwang, W.Y., and J. Foote. 2005. Immunogenicity of engineered antibodies. Methods 36:3-10.
67. Itakura, K., T. Hirose, R. Crea, A.D. Riggs, H.L. Heyneker, F. Bolivar, and H.W. Boyer. 1977. Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin. Science 198:1056-1063.
68. Jefferis, R. 2007. Antibody therapeutics: Isotype and glycoform selection. Expert Opin. Ther. 7:1401-1413.
69. Jerne, N.K., and A.A. Nordin. 1963. Plaque formation in agar by single antibody-producing cells. Science 140:405.
70. Jones, P.T., P.H. Dear, J. Foote, M.S. Neuberger, and G. Winter. 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522-525.
71. Kabat, E.A., T.T. Wu, M. Reid-Miller, H.M. Perry, and K.S. Gottesman. 1987. Sequences of proteins of immunological interest. Washington, D.C.: U.S. Department of Health and Human Services. Publ. No. 91-3242.
72. Kalwy, S., J. Rance, and R. Young. 2006. Toward more efficient protein expression: Keep the message simple. Mol. Biotechnol. 34:151-156.
73. Kaneko, Y., F. Nimmerjahn, and J.V. Ravetch. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670-673.
74. Kimball, J.A., D.J. Norman, C.F. Shield, T.J. Schroeder, P. Lisi, M. Garovoy, J.B. O'Connell, F. Stuart, S.V. McDiarmid, and W. Wall. 1995. The OKT3 antibody response study: A multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation. Transpl. Immunol. 3(3):212-221.
75. KMR Group, Inc. 2007. Benchmarking biopharmaceutical industry, Chicago.
76. Knappik, A., L. Ge, A. Honegger, P. Pack, M. Fischer, G. Wellnhofer, A. Hoess, J. Wolle, A. Pluickthun, and B. Virnekas. 2000. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296:57-86.
77. Kohler, G., and C. Milstein. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
78. Kung, P., G. Goldstein, E.L. Reinherz, and S.F. Schlossman. 1979. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 206:347-349.
79. Kuter, D.J. 2007. New thrombopoietic growth factors. Blood 109:4607-4616.
80. Laffly, E., and R. Sodoyer. 2005. Monoclonal and recombinant antibodies, 30 years after.. Human Antibodies 14:33-55.
81. Lawley, T.J., L. Bielory, P. Gascon, K.B. Yancey, N.S. Yound, and M.M. Frank. 1984. A prospective clinical and immunologic analysis of patients with serum sickness. New Engl. J. Med. 311:1407-1413.
82. Lazar, G.A., W. Dang, S. Karki, O. Vafa, J.S. Peng, L. Hyun, C. Chan, H.S. Chung, A. Eivazi, S.C. Yoder, J. Veilmetter, D.F. Carmichael, R.J. Hayes, and B.I. Dahiyat. 2006. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103:4005-4010.
83. Leader, B., Q.J. Baca, and D.E. Golan. 2008. Protein therapeutics: A summary and pharmacological classification. Nature Rev. Drug Discov. 7:21-39.
84. Leonard, J.P., P. Martin, J. Ruan, R. Elstom, J. Barrientos, M. Coleman, and R.R. Furman. 2008. New monoclonal antibodies for non-Hodgkin's lymphoma. Annals Oncol. 19:iv60-iv62.
85. Li, H., N. Sethuraman, T.A. Stadheim, D. Zha, B. Prinz, N. Ballew, P. Bobrowicz, B.K. Choi, W.J. Cook, M. Cukan, N.R. Houston-Cummings, R. Davidson, B. Gong, S.R. Hamilton, J.P. Hoopes, Y. Jiang, N. Kim, R. Mansfield, J.H. Nett, S. Rios, R. Strawbridge, S. Wildt, and T.U. Gerngross. 2006. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nature Biotechnol. 24:210-215.
86. Llewelyn, M.B., R.E. Hawkins, and S.J. Russell. 1992. Discovery of antibodies. Br. Med. J. 305:1269-1272.
87. Lobo, P.I., and H.C. Patel. 1997. Murine monoclonal IgG antibodies: Differences in their IgG isotypes can affect the antibody effector activity when using human cells. Immunol. Cell Biol. 75:267-274.
88. Lonberg, N. 2005. Human antibodies from transgenic animals. Nature Biotechnol. 23:1117-1125.
89. Lonberg, N., L.D. Taylor, F.A. Harding, M. Trounstine, K.M. Higgins, S.R. Schramm, C.C. Kuo, R. Mashayekh, K. Wymore, J.G. McCabe, et al. 1994. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368:856-859.
90. Lowman, H.B., S.H. Bass, N. Simpson, and J.A. Wells. 1991. Selecting high-affinity binding proteins by monovalent phage display. Biochemistry. 30:10832-10838.
91. Maloney, D.G. 2007. Follicular NHL: From antibodies and vaccines to graft-versus-lymphoma effects. Hematology Am. Soc. Hematol. Educ. Program 2007:226-232.
92. Markland, W., B.L. Roberts, M.J. Saxena, S.K. Guterman and R.C. Ladner. 1991. Design, construction and function of a multicopy display vector using fusions to the major coat protein of bacteriophage M13. Gene 109:13-19.
93. Marks, J.D., H.R. Hoogenboom, T.P. Bonnert, J. McCafferty, A.D. Griffiths, and G. Winter. 1991. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:581-597.
94. Marks, J.D., A.D. Griffiths, M. Malmgvist, T.P. Clackson, J.M. Bye, and G. Winter. 1992. By-passing immunization: Building high affinity human antibodies by chain shuffling. Biotechnology (NY) 10:779-783.
95. Marks, J.D., H.R. Hoogenboom, A.D. Griffiths, and G. Winter. 1992. Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system. J. Biol. Chem. 267:16007-16010.
96. Masuda, K., T. Kubota, E. Kaneko, S. Iida, M. Wakitani, Y. Kobayashi-Natsume, A. Kubota, K. Shitara, and K. Nakamura. 2007. Enhanced binding affinity for FcgammaRllla of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol. Immunol. 44:3122-3131.
97. McCafferty, J., A.D. Griffiths, G. Winter, and D.J. Chiswell. 1990. Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 348:552-554.
98. Milstein, C. 1985. From the structure of antibodies to the diversification of the immune response. Nobel lecture, 8 December 1984. Biosci. Rep. 5:275-297.
99. Mondon, P., O. Dubreuli, K. Bouayadi, and H. Kharrat. 2008. Human antibody libraries: A race to engineer and explore a larger diversity. Front. Biosci. 13:1117-1129.
100. Morrison, S.L., M.J. Johnson, L.A. Herzenberg, and V.T. Oi. 1984. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81:6851-6855.
101. Mouthon, L., and O. Lortholary. 2003. Intravenous immunoglobulins in infectious diseases: Where do we stand? Clin. Microbiol. Infect. 9:333-338.
102. Mullis, K., F. Faloona, S. Scharf, R. Saiki, G. Horn, and H. Erlich. 1986. Specific enzymatic amplification of DNA in vitro: The polymerase chain reaction. Cold Spring Harbor Symp. Quant. Biol. 51(pt. 1):263-273.
103. Neuberger, M.S. 1983. Expression and regulation of immunoglobulin heave chain gene transfected into lymphoid cells. EMBO J. 1373-1378.
104. Neuberger, M.S., and G.T. Williams. 1986. Construction of novel antibodies by use of DNA transfection: Design of plasmid vectors. Philos. Trans. R. Soc. LondonA 317:425-432.
105. Neuberger, M.S., G.T. Williams, and R.O. Fox. 1984. Recombinant antibodies possessing novel effector functions. Nature 312:604-608.
106. Nimmerjahn, F., and J.V. Ravetch. 2007. The anti-inflammatory activity of IgG: The intravenous IgG paradox. J. Exp. Med. 204:11-15.
107. Niwa, R., S. Hatanaka, E. Shoji-Hosaka, M. Sakurada, Y. Kobayashi, A. Uehara, H. Yodoi, K. Nakamura, and K. Shitara. 2004. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcgammaRllla functional polymorphism. Clin. Cancer Res. 10:6248-6255.
108. Orange, J.S., E.M. Hossny, C.R. Weiler, M. Ballow, M. Berger, F.A. Bonilla, R. Buckley, J. Chinen, Y. El-Gamal, B.D. Mazer, R.P. Nelson, Jr., D.D. Patel, E. Secord, R.U. Sorensen, R.L. Wasserman, and C. Cunningham-Rundles; Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. 2006. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 117:S525-S553.
109. Orlandi, R., D.H. Gussow, P.T. Jones, and G. Winter. 1989. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86:3833-3837.
110. Osbourn, J., M. Groves, and T. Vaughan. 2005. From rodent reagents to human therapeutics using antibody guided selection. Methods 36:61-68.
111. Ostberg, L., and C. Queen. 1995. Human and humanized monoclonal antibodies: Preclinical studies and clinical experience. Biochem. Soc. Trans. 23:1038-1043.
112. Paulus, H. 1985. Preparation and biomedical applications of bispecific antibodies. Behring Inst. Mitt. 78:118-132.
113. Pendley, C., A. Schantz, and C. Wagner. 2003. Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Therap. 5:172-179.
114. Petkova, S.B., S. Akilesh, T.J. Sproule, G.J. Christianson, H. AlKhabbaz, A.C. Brown, L.G. Presta, Y.G. Meng, and D.C. Roopenian. 2006. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: Potential application in humorally mediated autoimmune disease. Int. Immunol. 18:1759-1769.
115. Picha, K.M., M.R. Cunningham, D.J. Drucker, A. Mathur, T. Ort, M. Scully, A. Soderman, T. Spinka-Doms, V. Stojanovic-Susulic, B.A. Thomas, and K.T. O'Neil. 2008. Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis. Diabetes 57:1926-1934.
116. Presta, L.G. 2006. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv. Drug Deliv. Rev. 58:640-656.
117. Presta, L.G. 2008. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol. 20:460-470.
118. Queen, C., W.P. Schneider, H.E. Selick, P.W. Payne, N.F. Landolfi, J.F. Duncan, N.M. Avdalovic, M. Levitt, R.P. Junghans, and T.A. Waldmann. 1989. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA 86:10029-10033.
119. Rasmussen, S.K., L.K. Rasmussen, D. Weilguny, and A.B. Tolstmp. 2007. Manufacture of recombinant polyclonal antibodies. Biotechnol. Lett. 29:845-852.
120. Reff, M.E., K. Carner, K.S. Chambers, P.C. Chinn, J.E. Loenard, R. Raab, R.A. Newman, N. Hanna, and D.R. Anderson. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445.
121. Richards, J.O., S. Karki, G.A. Lazar, H. Chen, W. Dang, and J.R. Desjarlais. 2008. Optimization of antibody binding to FcgRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Therap. 7:2517-2527.
122. Ridgeway, J.B., L.G. Presta, and P. Carter. 1996. "Knobs-into-holes" engineering of antibody CH2 domains for heavy chain heterodimerization. Protein Eng. 9:617-621.
123. Riley, S. 2006. The future of monoclonal antibodies therapeutics: Innovation in antibody engineering, key growth strategies and forecasts to 2011. Datamonitor Report. London: Business Insights, Inc.
124. Roguska, M.A., J.T. Pedersen, A.H. Henry, S.M.J. Searle, C.M. Roja, B. Avery, M. Hoffee, S. Cook, J.M. Lambert, W.A. Blaettler, A.R. Rees, and B.C. Guild. 1996. A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing. Protein Eng. 9:895-904.
125. Roguska, M.A., J.T. Pedersen, C.A. Keddy, A.H. Henry, S.J. Searle, J.M. Lambert, V.S. Goldmacher, W.A. Blaettler, A.R. Rees, and B.C. Guild. 1994. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl. Acad. Sci. USA 91:969-973.
126. Rothe, C., S. Urlinger, C. Lohning, J. Prassier, Y. Stark, U. Jager, B. Hubner, M. Bardroff, I. Pradel, M. Boss, R. Bittlingmaier, T. Bataa, C. Frisch, B. Brocks, A. Honegger, and M. Urban. 2008. The human combinatorial antibody library HuCAC GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J. Mol. Biol. 376:1182-1200.
127. Rother, R.P., S.A. Rollins, C.J. Mojcik, R.A. Brodsky, and L. Bell. 2007. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature Biotechnol. 25:1256-1264.
128. Saiki, R.K., D.H. Gelfand, S. Stoffel, S.J. Scharf, R. Higuchi, G.T. Horn, K.B. Mullis, and H.A. Erlich. 1988. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487-491.
129. Shen, J., M.D. Vil, X. Jimenez, M. Iacolina, H. Zhang, and Z. Zhu. 2006. Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies. J. Biol. Chem. 281:10706-10714.
130. Shen, J. and Z. Zhu. 2008. Catumaxomab, a rat murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Curr. Opin. Mol. Ther. 10:273-284.
131. Shields, R.L., J. Lai, R. Keck, L.Y. O'Connell, K. Hong, Y.G. Meng, S.H. Weikert, and L.G. Presta. 2002. Lack of fructose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma Rlll and antibody-dependent cellular toxicity. J. Biol. Chem. 277:26733-26740.
132. Shields, R.L., A.K. Namenuk, K. Hog, Y.G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, J.A. Fox, and L.G. Presta. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276:6591-6604.
133. Shin, S.U., and S.L. Morrison. 1989. Production and properties of chimeric antibody molecules. Methods Enzymol. 178:459-476.
134. Shook, R.L. 2007. Miracle medicines. Seven lifesaving drugs and the people who created them. New York: Penguin Books.
135. Sidhu, S.S., and F.A. Fellouse. 2006. Synthetic therapeutic antibodies. Nature Chem. Biol. 2:682-688.
136. Silverstein, A.M. 2003. Splitting the difference: The germline-somatic mutation debate on generating antibody diversity. Nature Immunol. 4:829-833.
137. Skerra, A., and A. Plückthun. 1988. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240:1038-1040.
138. Smith, G.P. 1985. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 228:1315-1317.
139. Staelens, S., J. Desmet, T.H. Ngo, S. Vauterin, I. Pareyn, P. Barbeaux, I. Van Rompaey, J.-M. Stassen, H. Deckmyn, and K. Vanhoorelbeke. 2006. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modeling of variable domains. Mol. Immunol. 43:1243-1257.
140. Staerz, U.D., and M.J. Bevan. 1986. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc. Natl. Acad. Sci. USA 83:1453-1457.
141. Stockwin, L.H. and S. Holmes. 2003. Antibodies as therapeutic agents: vive la renaissance! Expert Opin. Biol. Ther. 3:1133-1152.
142. Tang, Y., J. Lou, R.K. Alpaugh, M.K. Robinson, J.D. Marks, and L.M. Weiner. 2007. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J. Immunol. 179:2815-2823.
143. Tax, W.F., F.F. Hermes, R.W. Willems, P.J. Capel, and R.A. Koene. 1984. Fc receptors for mouse IgG1 on human monocytes: Polymorphism and role in antibody-induced T cell proliferation. J. Immunol. 133:1185-1189.
144. Teeling, J.L., R.R. French, M.S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P.W. Parren, C.E. Hack, M. Dechant, T. Valerius, J.G. van de Winkel, and M.J. Glennie. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104:1793-1800.
145. Tonegawa, S. 1983. Somatic generation of antibody diversity. Nature 302:575-581.
146. Umana, P., E. Moessner, P. Bruenker, et al. 2006. Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. Blood 108:229a.
147. Vaughan, T.J., A.J. Williams, K. Pritchard, J.K. Osbourn, A.R. Pope, J.C. Earnshaw, J. McCafferty, R.A. Hodits, F. Wilton, and K.S. Johnson. 1996. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nature Biotechnol. 14:309-314.
148. Wallington, T. 2004. New uses for IVIgG immunoglobulin therapies. Vox Sanguinis 87:S155-S157.
149. Weil, A.J., J.A. Pafentjiev, and K.L. Bowman. 1938. Antigenic qualities of antitoxins. J. Immunol. 35:399-413.
150. Weiler, C.R. 2004. Immunoglobulin therapy: History, indications, and routes of administration. Int. J. Dermatol. 43:163-166.
151. Weiner, G.J., J.A. Bowles, B.K. Link, M.A. Campbell, J.E. Wooldridge, J.B. Breitmeyer. 2005. Anti-CD20 monoclonal antibody (mAb) with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab (R). Blood 106:348a.
152. Weng, W.K., and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21:3940-3947.
153. Wilberg, F.C., S.K. Rasmussen, T.P. Frandsen, L.K. Rasmussen, K. Tengbjerg, V.W. Coljee, J. Sharon, C.Y. Yang, S. Bregenholt, L.S. Nielsen, J.S. Harum, and A.B. Tolstrup. 2006. Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol. Bioeng. 94:396-405.
154. Wilde, H., P. Thipkong, V. Sitprija, and N. Chaiyabutr. 1996. Heterologous antisera and antivenins are essential biologics: Perspectives on a worldwide crisis. Ann. Intern. Med. 125:233-236.
155. Winau, F., and R. Winau. 2002. Emil von Behring and serum therapy. Microbes Infect. 4:185-188.
156. Winau, F., O. Westphal, and R. Winau. 2004. Paul Ehrlich-in search of the magic bullet. Microbes Infect. 6:786-789.
157. Wu, H., D.S. Pfarr, Y. Tang, L.L. An, N.K. Patel, J.D. Watkins, W.D. Huse, P.A. Kiener, and J.F. Young. 2005. Ultra-potent antibodies against respiratory syncytial virus: Effects of binding kinetics and binding valence on viral neutralization. J. Mol. Biol. 350:126-144.
158. Wu, H., D.S. Pfarr, S. Johnson, Y.A. Brewah, R.M. Woods, N.K. Patel, W.I. White, J.F. Young, and P.A. Kiener. 2007a. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368:652-665.
159. Wu, C., H. Ting, C. Grinnell, S. Bryant, R. Miller, A. Clabbers, S. Bose, D. McCarthy, R.R. Zhu, L. Santora, R. Davis-Taber, Y. Kunes, E. Fung, A. Schwartz, P. Sakorafas, J. Gu, E. Tarcsa, A. Murtaza, and T. Ghayur. 2007b. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nature Biotechnol. 25:1290-1297.
160. Xu, D., M.L. Alegre, S.S. Varga, A.L. Rothermel, A.M. Collins, V.L. Pulito, L.S. Hanna, K.P. Dolan, P.W. Parren, J.A. Bluestone, L.K. Jolliffe, and R.A. Zivin. 2000. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 200:16-26.
161. Xu, L., H. Yee, C. Chan, A.K. Kashyap, L. Horowitz, M. Horowitz, R.R. Bhatt, and R.A. Lerner. 2008. Combinatorial surrobody libraries. Proc. Natl. Acad. Sci. USA 105:10762-10767.
162. Zeidler, R., G. Reisbach, B. Wollenberg, S. Lang, S. Chaubel, B. Schmitt, and H. Lindhofer. 1999. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J. Immunol. 163:1246-1252.
163. Ziegelbauer, K., and D.R. Light. 2008. Monoclonal antibody therapeutics: Leading companies to maximize sales and market share. J. Commercial Biotechnol. 14:65-72.
164. Zoller, M.J., and M. Smith. 1982. Oligonucleotide-directed mutagenesis using M13-derived vectors: An efficient and general procedure for the production of point mutations in any fragment of DNA. Nucleic Acids Res. 10:6487-6500.